Asymmetric dimethylarginine and its relation as a biomarker in nephrologic diseases
Biomarker Insights, cilt.11, ss.131-137, 2016 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 11
- Basım Tarihi: 2016
- Doi Numarası: 10.4137/bmimi.s38434
- Dergi Adı: Biomarker Insights
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.131-137
- Anahtar Kelimeler: Asymmetric dimethylarginine, Biomarker, Endothelial dysfunction, Nitric oxide, Oxidative stress, Renal failure
- Maltepe Üniversitesi Adresli: Evet
Özet
It is encouraging to observe that a search for publications on “asymmetric dimethylarginine (ADMA)” in PubMed, as updated on June 2016, yielded>2500 items, 24 years after a splendid paper published by Vallance et al in which the authors proposed that ADMA accumulation could be a cardiovascular risk factor in chronic kidney diseases. ADMA is the endogenous inhibitor of nitric oxide synthase and is related to endothelial dysfunc-tion, which plays an important role in vascular damage elicited by various cardiometabolic risk factors. Although current knowledge suggests that ADMA has critical central roles in renal diseases, there are still unexplained details. The present article aims to provide a review on ADMA and its relation as a biomarker in nephrologic diseases. We aimed to systematize articles in which ADMA levels were assessed in order to clarify its role in many diseases and establish its reference values in different populations.